CardioDx to price initial public stock sale at $14.00-$16.00

BofA Merrill Lynch and Jefferies are joint bookrunning managers

By Devika Patel

Knoxville, Tenn., Nov. 4 - CardioDx, Inc. will sell 5 million common shares in its initial public offering with a 30-day greenshoe of 750,000 additional shares, according to a Form S-1/A filed Monday with the Securities and Exchange Commission. The deal was announced Oct. 11.

The shares will be sold at a price expected to fall between $14.00 and $16.00 per share.

BofA Merrill Lynch and Jefferies are the joint bookrunning managers. Piper Jaffray and William Blair are the co-managers.

Proceeds will be used for working capital, to cover operating losses, to conduct additional clinical and marketing activities, for research and development and for general corporate purposes.

The molecular diagnostics company is based in Palo Alto, Calif. It intends to list its common stock on the Nasdaq under the symbol "CDX."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.